Latest news
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.commarketbeat.com · Sat, 08 Aug 2026 00:16:46 GMT[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock TitanStock Titan · Fri, 07 Aug 2026 01:08:56 GMTSpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:22:06 GMTSpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 20:37:00 GMTSpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingViewTradingView · Thu, 06 Aug 2026 20:35:16 GMTSpyGlass Pharma Q2 net loss widens on higher expenses - TradingViewTradingView · Thu, 06 Aug 2026 20:21:35 GMTSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 20:05:00 GMTSpyGlass glaucoma trial enrollment remains on track for 2027 - Stock TitanStock Titan · Thu, 06 Aug 2026 20:05:00 GMT